Related Experiment Videos
Genomic approaches to clinical drug resistance
Sambasivarao Damaraju1, Michael Sawyer, Brent Zanke
1Polyomx Program (www.polyomx.org), Department of Experimental Oncology, Cross Cancer Institute, Edmonton, Alberta, Canada.
Cancer Treatment and Research
|December 17, 2002
Abstract
No abstract available in PubMed .
Related Concept Videos
Articles linked to this work by shared authors, journal, and citation graph.
Circadian rhythm disruption is related to self-diagnosis of mental illness.
Discover mental health·2025
Pathways Contributing to Chemotherapy-Induced Myotoxicity Are Attenuated by EPA + DHA in a Clinically Relevant Model of Colorectal Cancer.
Journal of cachexia, sarcopenia and muscle·2025
Protocol for an intervention for new parents experiencing moderate psychosocial adversity: pilot feasibility randomised trial.
Journal of reproductive and infant psychology·2024
P-Factor(s) for Youth Psychopathology Across Informants and Models in 24 Societies.
Journal of clinical child and adolescent psychology : the official journal for the Society of Clinical Child and Adolescent Psychology, American Psychological Association, Division 53·2024
Clinical Trials and Translational Advances in Metabolic Targeting.
Cancer treatment and research·2026
Tools and Technologies for Studying Cancer Metabolism.
Cancer treatment and research·2026
Cancer and Immune Cells: A Metabolic Battle in the Tumor Microenvironment.
Cancer treatment and research·2026
Biomarkers of Cancer Metabolism and Therapeutic Response.
Cancer treatment and research·2026
Targeting Metabolism in Cancer Therapy: Inhibitors and Approaches.
Cancer treatment and research·2026
Metabolic Reprogramming in Cancer Stem Cells.
Cancer treatment and research·2026
Multi-Omics Genome-Wide to Explore the Formation and Development Targets for Intracranial Aneurysms.
FASEB journal : official publication of the Federation of American Societies for Experimental Biology·2026
Regulatory and Quality Considerations of Antibody-drug Conjugates.
AAPS PharmSciTech·2026
HDAC inhibition via suberoylanilide hydroxamic acid ameliorates doxorubicin-induced cardiotoxicity.
Nature communications·2026